RHABDOMYOSARCOMA

This study tests a new treatment called AGAR T cells for children whose solid tumors (like liver cancer or Wilms tumor) have returned or not responded to standard care. The treatment involves taking a patient's own immune cells, adding genes to help them recognize and attack tumo…

This early-phase study tests a personalized cell therapy for children and young adults (up to age 26) with solid tumors that have come back or not responded to standard treatment. The therapy uses the patient's own immune cells, modified to recognize and attack a protein called B…

This study tests a combination of two drugs, cobolimab and dostarlimab, in children and young adults (up to age 21) with advanced solid tumors that have not responded to other treatments. The goal is to find the safest dose and see if the drugs can shrink tumors. The study involv…

This study tests a drug called cabozantinib in children and young adults (up to age 30) with rare cancers like sarcomas, Wilms tumor, and others that have come back or not responded to standard therapy. The drug works by blocking enzymes that help tumors grow and form blood vesse…

This early-phase study tests an experimental drug called CLR 131 in 30 children, adolescents, and young adults whose solid tumors, lymphoma, or brain tumors have returned or not responded to standard treatments. The main goal is to find a safe dose and check for side effects. Par…

This study tests four different chemotherapy schedules in children with a rare, aggressive muscle cancer that has spread. The goal is to see if changing when and how chemo is given can keep the cancer away longer and cause fewer side effects. Patients and their doctors choose fro…

This early-stage study tests a flavored, drinkable chemotherapy called VAL-413 (Orotecan) combined with another drug (temozolomide) in children and young adults up to age 30 whose solid tumors have come back. The main goal is to find the safest dose and see how the body processes…

This study tests a new drug called PEN-866 combined with two standard chemotherapy drugs (vincristine and temozolomide) in people aged 12 to 39 whose solid tumors, including Ewing sarcoma and rhabdomyosarcoma, have come back or not responded to standard treatments. The goal is to…

This early-stage study tests a personalized cell therapy for children and young adults (ages 1–30) with solid tumors that have come back or not responded to treatment. The therapy uses the patient's own immune cells, modified to recognize and attack tumors that carry a protein ca…

This early-stage trial tests a new treatment called CATCH T cells for people with certain solid tumors that have come back or not responded to standard care. The treatment involves taking a patient's own immune cells, adding new genes to help them recognize and attack cancer cell…

This study compares standard chemotherapy (VAC/VI) to the same chemo plus temsirolimus in people up to age 40 with intermediate-risk rhabdomyosarcoma, a muscle cancer. The goal is to see if adding temsirolimus improves event-free survival (time without cancer worsening or returni…

This study tests a technique called image-guided radiation therapy (IGRT) for children and young adults with bone or soft tissue tumors. IGRT uses detailed scans (CT, MRI, PET) to target the tumor very precisely, aiming to destroy the cancer while protecting healthy tissue. The g…

This study is for children newly diagnosed with rhabdomyosarcoma, a rare muscle cancer. It uses a personalized approach with proton beam radiation, surgery, and standard or stronger chemotherapy based on the child's risk level. Children with higher-risk cancer also receive extra …

This early-stage study tests whether a personalized immune cell therapy called TIL is safe and can fight cancer in children, teenagers, and young adults (ages up to 21) with solid tumors that have come back or stopped responding to standard treatments. Participants receive their …

This study looks at whether a special PET scan using a natural substance called methionine can help doctors see tumors in children and young adults with cancer. About 500 participants will get the scan to check if it can find tumors, tell how aggressive they are, and tell leftove…

This study explores whether special MRI scans can measure oxygen levels (hypoxia) in children's sarcoma tumors before and after chemotherapy. The goal is to see if these scans can help doctors personalize treatment plans. The study involves 18 children and teens aged 6-18 with so…